| Clinical data | |
|---|---|
| Other names | 5,6-Dihydro-2-methyl-4-[4-nitro-3-(trifluoromethyl)phenyl]-2H-1,2,4-oxadiazin-3-(4H)-one[1] |
| Drug class | Nonsteroidal antiandrogen |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C11H10F3N3O4 |
| Molar mass | 305.213 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
RU-22930 is anonsteroidal antiandrogen (NSAA) related to the NSAAsflutamide andnilutamide (RU-23908) and was developed byRoussel Uclaf but was never marketed.[2][3] It is aselectiveantagonist of theandrogen receptor and consequently hasprogonadotropic effects by increasinggonadotropin andtestosterone levels via disinhibition of thehypothalamic-pituitary-gonadal axis.[2] Unlike flutamide and nilutamide, the drug is said to be short-acting and inactive byinjection, but it has been found to be activetopically in animals, and hence could be useful for the treatment ofandrogen-dependentskin conditions.[2][4]
Thisdrug article relating to thegenito-urinary system is astub. You can help Wikipedia byexpanding it. |